{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T15:09:42Z","timestamp":1771686582533,"version":"3.50.1"},"reference-count":90,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T00:00:00Z","timestamp":1335139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The goals of optimal medical therapy in patients with stable angina pectoris are to reduce the risk of cardiovascular mortality and future cardiovascular events, improve exercise capacity, and enhance quality of life. Whereas myocardial revascularization is frequently employed in the management of patients with stable angina, a variety of pharmacologic interventions are recommended as part of optimal medical management. The use of short\u2010 and rapidly\u2010acting nitrates (eg, sublingual nitroglycerin spray and tablets) is at the core of the therapeutic armamentarium and should be integrated into optimal medical therapy for stable angina along with exercise therapy. The potential clinical implications from these observations are that prophylactic sublingual nitrates, when combined with cardiac rehabilitation, may allow the patient with angina to exercise to a greater functional capacity than without sublingual nitrates.<jats:italic>Clin. Cardiol.<\/jats:italic>2012 DOI: 10.1002\/clc.21993<\/jats:p><jats:p>William E. Boden: Advisory Board for Arbor Pharmaceuticals. Aloke V. Finn: Sponsored research agreement with Medtronic Vascular; Scientific Advisory Board for Medtronic Vascular; Advisory Board for Arbor Pharmaceuticals. Dharmesh Patel: Speakers Bureau for Novartis, Arbor Pharmaceuticals, Medtronic, Takeda Pharmaceuticals, Abbott, St Jude's Medical, Cleveland Heart Lab, Boston Heart Lab, Forrest Pharmaceuticals, Boehringer Ingelheim, and Jansen &amp; Jansen. W. Frank Peacock: Advisory Board for Abbott, Alere, Arbor Pharmaceuticals, Lilly, and The Medicines Co; Received research grants from Alere, Brahms Comprehensive Research Associates, Electrocore, Novartis, The Medicines Co; Speakers Bureau for Abbott, Alere, and Electrocore; Ownership interest in EKR, Emergencies in Medicine, and Vital Sensors. Udho Thadani: Received consultation fee from Arbor Pharmaceuticals for interpretation of the study data and for writing this manuscript; Advisory Board for Arbor Pharmaceuticals; Consultant for Gilead Sciences, Astra Zeneca, Pfizer, Merck, Bristol\u2010Myers Squibb, Bayer, Forest Laboratories, and Servier; Speaker's program for Eli Lilly and Daiichi\u2010Sankyo and Gilead Sciences. Franklin H. Zimmerman: Advisory Board for Arbor Pharmaceuticals; Speakers Bureau for Boerhinger\u2010Ingelheim.<\/jats:p><jats:p><jats:sup>**<\/jats:sup>At the time this manuscript was written, Dr Peacock's affiliation was: Department of Emergency Medicine, The Cleveland Clinic, Cleveland, Ohio.<\/jats:p>","DOI":"10.1002\/clc.21993","type":"journal-article","created":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T20:26:33Z","timestamp":1335212793000},"page":"263-271","source":"Crossref","is-referenced-by-count":30,"title":["Nitrates as an Integral Part of Optimal Medical Therapy and Cardiac Rehabilitation for Stable Angina: Review of Current Concepts and Therapeutics"],"prefix":"10.1002","volume":"35","author":[{"given":"William E.","family":"Boden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aloke V.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharmesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Frank Peacock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udho","family":"Thadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin H.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,23]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1161\/CIR.0b013e3182009701","article-title":"Heart disease and stroke statistics\u20142011 update: a report from the American Heart Association [published corrections appear in","volume":"123","author":"Roger VL","year":"2011","journal-title":"Circulation."},{"key":"e_1_2_10_3_2","unstructured":"World Health Organization. World Health Organization Fact Sheet No. 317: cardiovascular diseases (CVDs).http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/index.html. Published September2011.Accessed December 14 2011."},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00028-6"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/heart.87.2.140"},{"key":"e_1_2_10_6_2","first-page":"e260","article-title":"Heart disease and stroke statistics\u20142010 update: a report from the American Heart Association [published corrections appear in","volume":"121","author":"Lloyd\u2010Jones D","year":"2010","journal-title":"Circulation."},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200522110-00003"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl005"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.01.037"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.10.1193"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl001"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.125505"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104123441502"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.12.082"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070829"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804626"},{"key":"e_1_2_10_17_2","first-page":"S358","article-title":"Cost of illness of chronic angina.","volume":"10","author":"Javitz HS","year":"2004","journal-title":"Am J Manag Care."},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.02.036"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02848-6"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/107424840400900103"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8651(18)30319-9"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.08.015"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.187930"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.10.824"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-011-0238-6"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07298-X"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.521864"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.9.2335"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00204-5"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805796"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S11100"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000086629.67552.3A"},{"key":"e_1_2_10_34_2","first-page":"642","article-title":"Nitroglycerin as a remedy for angina pectoris.","volume":"113","author":"Murell W.","year":"1879","journal-title":"Lancet."},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.67.1.124"},{"key":"e_1_2_10_36_2","first-page":"41","article-title":"Glycerol trinitrate and coronary heart disease: value of prophylactic administration within the scope of exercise therapy [article in German].","volume":"116","author":"Kolenda KD.","year":"1998","journal-title":"Fortschr Med."},{"key":"e_1_2_10_37_2","first-page":"109","article-title":"Increased physical performance following administration of glycerol trinitrate in spray form [article in German].","volume":"117","author":"Wittig T","year":"1999","journal-title":"Fortschr Med."},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.5.667"},{"key":"e_1_2_10_39_2","first-page":"36","volume-title":"Drugs for the Heart.","author":"Thadani U","year":"1995"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.77.6.1376"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1135-5_5"},{"key":"e_1_2_10_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(89)90216-7"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00053031"},{"key":"e_1_2_10_44_2","unstructured":"Nitro\u2010Dur [prescribing information]. Summit NJ: Key Pharmaceuticals Inc.;2006."},{"key":"e_1_2_10_45_2","volume-title":"Nitrolingual Pumpspray [prescribing information].","year":"2011"},{"key":"e_1_2_10_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.2.8.880"},{"key":"e_1_2_10_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0146-2806(88)90019-9"},{"key":"e_1_2_10_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(83)90393-X"},{"key":"e_1_2_10_49_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122225199"},{"key":"e_1_2_10_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)90489-N"},{"key":"e_1_2_10_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(10)80342-0"},{"key":"e_1_2_10_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1135-5_3"},{"key":"e_1_2_10_53_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc3501.095358"},{"key":"e_1_2_10_54_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0022-3565(25)32738-2","article-title":"Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S\u2010nitrosothiols as active intermediates.","volume":"218","author":"Ignarro LJ","year":"1981","journal-title":"J Pharmacol Exp Ther."},{"key":"e_1_2_10_55_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.83.4.1271"},{"key":"e_1_2_10_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(80)90643-8"},{"key":"e_1_2_10_57_2","first-page":"14","article-title":"Mechanism of nitrate\u2010induced vasodilation and tolerance.","volume":"72","author":"Kukovetz WR","year":"1983","journal-title":"Z Kardiol."},{"key":"e_1_2_10_58_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.79.1.188"},{"key":"e_1_2_10_59_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0022-3565(25)29462-9","article-title":"Mechanism of tolerance development to organic nitrates.","volume":"184","author":"Needleman P","year":"1973","journal-title":"J Pharmacol Exp Ther."},{"key":"e_1_2_10_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01729-1"},{"key":"e_1_2_10_61_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.23.2810"},{"key":"e_1_2_10_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198507000-00024"},{"key":"e_1_2_10_63_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.8.2545"},{"key":"e_1_2_10_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00392-1"},{"key":"e_1_2_10_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00085-0"},{"key":"e_1_2_10_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00398-2"},{"key":"e_1_2_10_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198709243171304"},{"key":"e_1_2_10_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00656-1"},{"key":"e_1_2_10_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00705-1"},{"key":"e_1_2_10_70_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000146906.42375.D3"},{"key":"e_1_2_10_71_2","volume-title":"Muse (alprostadil) urethral suppository [package insert].","year":"2011"},{"key":"e_1_2_10_72_2","first-page":"44","volume-title":"Autonomic Nervous System in Old Age.","author":"Bourke E","year":"2004"},{"key":"e_1_2_10_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960250908"},{"key":"e_1_2_10_74_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000151788.08740.5C"},{"key":"e_1_2_10_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.01.009"},{"key":"e_1_2_10_76_2","doi-asserted-by":"publisher","DOI":"10.1097\/PHM.0b013e31821f71a6"},{"key":"e_1_2_10_77_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.502591"},{"key":"e_1_2_10_78_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000121360.31954.1F"},{"key":"e_1_2_10_79_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.23.3106"},{"key":"e_1_2_10_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90940-9"},{"key":"e_1_2_10_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.11.038"},{"key":"e_1_2_10_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.09.001"},{"key":"e_1_2_10_83_2","unstructured":"KushnerF.The New and Revised2011ACCF\/AHA PCI and CABG Guidelines: A Revascularization Consensus Is at the Heart of the Matter.http:\/\/my.americanheart.org\/professional\/General\/Revascularization\u2010Consensus\u2010is\u2010at\u2010the\u2010Heart\u2010of\u2010the\u2010Matter_UCM_433406_Article.jsp. Updated November 8 2011.Accessed March 2 2012."},{"key":"e_1_2_10_84_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000047041.66447.29"},{"key":"e_1_2_10_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00140-0"},{"key":"e_1_2_10_86_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960240604"},{"key":"e_1_2_10_87_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007043"},{"key":"e_1_2_10_88_2","volume-title":"Lopressor (metoprolol tartrate) tablets, USP [prescribing information].","year":"2011"},{"key":"e_1_2_10_89_2","volume-title":"Nitrostat (nitroglycerin sublingual) tablets, USP [prescribing information].","year":"2011"},{"key":"e_1_2_10_90_2","volume-title":"Cardizem (diltiazem hydrochloride) extended release tablets [prescribing information].","year":"2010"},{"key":"e_1_2_10_91_2","volume-title":"Ranexa (ranolazine) extended\u2010release tablets [prescribing information].","year":"2011"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.21993","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.21993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T11:10:31Z","timestamp":1742987431000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.21993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,23]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1002\/clc.21993"],"URL":"https:\/\/doi.org\/10.1002\/clc.21993","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,23]]}}}